Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatography

被引:33
作者
Chan, V [1 ]
Charles, BG [1 ]
Tett, SE [1 ]
机构
[1] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2004年 / 803卷 / 02期
基金
英国医学研究理事会;
关键词
leflunomide; A77; 1726;
D O I
10.1016/j.jchromb.2004.01.016
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple method for the measurement of the active leflunomide metabolite A77 1726 in human plasma by HPLC is presented. The sample workup was simple, using acetonitrile for protein precipitation. Chromatographic separation of A77 1726 and the internal standard, alpha-phenylcinnamic acid, was achieved using a C-18 column with UV detection at 305 nm. The assay displayed reproducible linearity for A77 1726 with determination coefficients (r(2)) > 0.997 over the concentration range 0.5-60.0 mug/ml. The reproducibility (%CV) for intra- and inter-day assays of spiked controls was <5%. The limit of quantification was 0.8 mug/ml. The average absolute recovery was approximately 100%. This assay is suitable for the determination of A77 1726 in plasma of patients taking leflunomide, and is simpler to use than other HPLC methods reported previously. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:331 / 335
页数:5
相关论文
共 13 条
[1]   In vivo activity of leflunomide - Pharmacokinetic analyses and mechanism of immunosuppression [J].
Chong, ASF ;
Huang, W ;
Liu, W ;
Luo, JL ;
Shen, JK ;
Xu, W ;
Ma, LL ;
Blinder, L ;
Xiao, F ;
Xu, XL ;
Clardy, C ;
Foster, P ;
Williams, JA .
TRANSPLANTATION, 1999, 68 (01) :100-109
[2]   MEASUREMENT OF THE ACTIVE LEFLUNOMIDE METABOLITE-(A77-1726) BY REVERSE-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
DIAS, VC ;
LUCIEN, J ;
LEGATT, DF ;
YATSCOFF, RW .
THERAPEUTIC DRUG MONITORING, 1995, 17 (01) :84-88
[3]  
Fox RI, 1998, J RHEUMATOL, V25, P20
[4]   Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis [J].
Goldenberg, MM .
CLINICAL THERAPEUTICS, 1999, 21 (11) :1837-1852
[5]  
Kaplan M J, 2001, Curr Opin Investig Drugs, V2, P222
[6]  
KROUWER JS, 1981, CLIN CHEM, V27, P202
[7]  
Li J, 2002, ACTA PHARMACOL SIN, V23, P551
[8]   SAFETY AND EFFECTIVENESS OF LEFLUNOMIDE IN THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID-ARTHRITIS - RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, PHASE-II STUDY [J].
MLADENOVIC, V ;
DOMLJAN, Z ;
ROZMAN, B ;
JAJIC, I ;
MIHAJLOVIC, D ;
DORDEVIC, J ;
POPOVIC, M ;
DIMITRIJEVIC, M ;
ZIVKOVIC, M ;
CAMPION, G ;
MUSIKIC, P ;
LOWFRIEDRICH, I ;
OED, C ;
SEIFERT, H ;
STRAND, V .
ARTHRITIS AND RHEUMATISM, 1995, 38 (11) :1595-1603
[9]  
Olsen NJ, 1999, B RHEUM DIS, V48, P1
[10]   Leflunomide - A review of its use in active rheumatoid arthritis [J].
Prakash, A ;
Jarvis, B .
DRUGS, 1999, 58 (06) :1137-1164